Skip to main content Accessibility help
×
Home

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

  • Le Xiao (a1) (a2), Xuequan Zhu (a1) (a2), Amy Gillespie (a3), Yuan Feng (a1) (a2), Jingjing Zhou (a1) (a2), Xu Chen (a1) (a2), Yuanyuan Gao (a4), Xueyi Wang (a4), Xiancang Ma (a5), Chengge Gao (a5), Yunshi Xie (a6), Xiaoping Pan (a6), Yan Bai (a7), Xiufeng Xu (a7), Gang Wang (a1) (a2) and Runsen Chen (a1) (a2) (a3)...

Abstract

Background

This study aimed to examine the efficacy of combining paroxetine and mirtazapine v. switching to mirtazapine, for patients with major depressive disorder (MDD) who have had an insufficient response to SSRI monotherapy (paroxetine) after the first 2 weeks of treatment.

Methods

This double-blind, randomized, placebo-controlled, three-arm study recruited participants from five hospitals in China. Eligible participants were aged 18–60 years with MDD of at least moderate severity. Participants received paroxetine during a 2-week open-label phase and patients who had not achieved early improvement were randomized to paroxetine, mirtazapine or paroxetine combined with mirtazapine for 6 weeks. The primary outcome was improvement on the Hamilton Rating Scale for Depression 17-item (HAMD-17) scores 6 weeks after randomization.

Results

A total of 204 patients who showed early non-response to paroxetine monotherapy were randomly assigned to receive either mirtazapine and placebo (n = 68), paroxetine and placebo (n = 68) or mirtazapine and paroxetine (n = 68), with 164 patients completing the outcome assessment. At week 8, the least squares (LS) mean change of HAMD-17 scores did not significantly differ among the three groups, (12.98 points) in the mirtazapine group, (12.50 points) in the paroxetine group and (13.27 points) in the mirtazapine plus paroxetine combination group. Participants in the paroxetine monotherapy group were least likely to experience adverse effects.

Conclusions

After 8 weeks follow-up, paroxetine monotherapy, mirtazapine monotherapy and paroxetine/mirtazapine combination therapy were equally effective in non-improvers at 2 weeks. The results of this trial do not support a recommendation to routinely offer additional treatment or a switch in treatment strategies for MDD patients who do not show early improvement after 2 weeks of antidepressant treatment.

Copyright

Corresponding author

Author for correspondence: Runsen Chen, E-mail: runsen.chen@psych.ox.ac.uk, Gang Wang, E-mail: gangwangdoc@vip.163.com

References

Hide All
Association, A. P. (2017). Practice guideline for the treatment of patients with major depressive disorder. 2010. Washington, DC: American Psychiatric Association.
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., & Möller, H.-J., & Disorders, W. T. F. o. T. G. f. U. D. (2015). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: Maintenance treatment of major depressive disorder-update 2015. The World Journal of Biological Psychiatry, 16(2), 7695.
Blier, P., Gobbi, G., Turcotte, J. E., de Montigny, C., Boucher, N., Hébert, C., & Debonnel, G. (2009a). Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation. European Neuropsychopharmacology, 19(7), 457465.
Blier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2009b). Combination of antidepressant medications from treatment initiation for major depressive disorder: A double-blind randomized study. American Journal of Psychiatry, 167(3), 281288.
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biological Psychiatry, 51(2), 183188.
Chen, R. (2018). Is there a role for tailoring treatment dose according to severity of symptoms? Bipolar Disorders, 20(2), 8586.
de Vries, Y. A., Roest, A. M., Bos, E. H., Burgerhof, J. G., van Loo, H. M., & de Jonge, P. (2019). Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: Individual patient data meta-analysis. The British Journal of Psychiatry 214(1), 410.
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., … Jiang, K. (2010). Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: A double-blind, randomized pilot study in a Chinese population. Journal of Clinical Psychopharmacology, 30(4), 357364.
Fava, M., Dunner, D. L., Greist, J. H., Preskorn, S. H., Trivedi, M. H., Zajecka, J., & Cohen, M. (2001). Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial. The Journal of Clinical Psychiatry, 62(6), 413420.
Galling, B., Sangroula, D., Ferrer, A. C., & Correll, C. (2016). Antidepressant augmentation and co-initiation treatment in acute major depressive disorder: A systematic review, meta-analysis and metaregression analysis. European Neuropsychopharmacology, 26, S459.
Gelenberg, A., Freeman, M., Markowitz, J., Rosenbaum, J., Thase, M., Trivedi, M., & Van Rhoads, R. (2017). Practice guideline for the treatment of patients with major depressive disorder 2010. In.
Gourion, D. (2008). Antidepressants and their onset of action: A major clinical, methodological and pronostical issue. L'Encephale, 34(1), 7381.
Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., & Kessler, R. C. (2015). The economic burden of adults with major depressive disorder in the United States (2005 and 2010). The Journal of Clinical Psychiatry, 76(2), 155162.
Guo, T., Xiang, Y.-T., Xiao, L., Hu, C.-Q., Chiu, H. F., Ungvari, G. S., … Geng, Y. (2015). Measurement-based care versus standard care for major depression: A randomized controlled trial with blind raters. American Journal of Psychiatry, 172(10), 10041013.
Katz, M. M., Tekell, J. L., Bowden, C. L., Brannan, S., Houston, J. P., Berman, N., & Frazer, A. (2004). Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology, 29(3), 566.
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., … MacQueen, G. M. (2016). Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 3. Pharmacological treatments. The Canadian Journal of Psychiatry, 61(9), 540560.
Knud, J. L. (2012). Mirtazapine versus other antidepressive agents for depression. Ugeskrift for laeger, 174(46), 28642866.
Kudlow, P. A., McIntyre, R. S., & Lam, R. W. (2014). Early switching strategies in antidepressant non-responders: Current evidence and future research directions. CNS drugs, 28(7), 601609.
Lam, R. W. (2012). Onset, time course and trajectories of improvement with antidepressants. European Neuropsychopharmacology, 22, S492S498.
Li, G., Zhang, H., Tao, l., & Huang, L. (2005). Compliance with paroxetine in the treatment of depression in primary care: a randomized comparison of initial dose 10 mg vs 20 mg. Chinese Mental Health Journal, 19(10), 715715.
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., … Murray, G. (2015). Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders. Australian & New Zealand Journal of Psychiatry, 49(12), 10871206.
Nakajima, S., Suzuki, T., Watanabe, K., Kashima, H., & Uchida, H. (2010). Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(2), 259264.
Nakajima, S., Uchida, H., Suzuki, T., Watanabe, K., Hirano, J., Yagihashi, T., … Mimura, M. (2011). Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(8), 19831989.
Posternak, M. A., & Zimmerman, M. (2005). Is there a delay in the antidepressant effect? A meta-analysis. In.
Szegedi, A., Jansen, W. T., van Willigenburg, A. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009). Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. The Journal of Clinical Psychiatry, 70, 344353.
Szegedi, A., Müller, M. J., Anghelescu, I., Klawe, C., Kohnen, R., & Benkert, O. (2003). Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. The Journal of Clinical Psychiatry, 64(4), 413420.
Tadić, A., Wachtlin, D., Berger, M., Braus, D. F., van Calker, D., Dahmen, N., … Helmreich, I. (2016). Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial. European Neuropsychopharmacology, 26(4), 705716.
Wagner, S., Engel, A., Engelmann, J., Herzog, D., Dreimüller, N., Müller, M. B., … Lieb, K. (2017). Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: Systematic review and meta-analysis. Journal of Psychiatric Research, 94, 96106.

Keywords

Type Description Title
WORD
Supplementary materials

Xiao et al. supplementary material
Appendix

 Word (78 KB)
78 KB

Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial

  • Le Xiao (a1) (a2), Xuequan Zhu (a1) (a2), Amy Gillespie (a3), Yuan Feng (a1) (a2), Jingjing Zhou (a1) (a2), Xu Chen (a1) (a2), Yuanyuan Gao (a4), Xueyi Wang (a4), Xiancang Ma (a5), Chengge Gao (a5), Yunshi Xie (a6), Xiaoping Pan (a6), Yan Bai (a7), Xiufeng Xu (a7), Gang Wang (a1) (a2) and Runsen Chen (a1) (a2) (a3)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed